Analysis of Hematological Examination Results in Pulmonary Tuberculosis (TB) Patients Undergoing Intensive Phase Anti-Tuberculosis Drug Therapy
The intensive phase of anti-tuberculosis (TB) drug therapy consists of a combination of antibiotics, including Isoniazid (INH), Rifampicin (RIF), Pyrazinamide (PZA), and Ethambutol (EMB). The primary goal of this therapy is to inhibit the growth and spread of Mycobacterium tuberculosis, preventin...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Universitas Nahdlatul Ulama Surabaya
2024-08-01
|
| Series: | Jurnal Ilmiah Kesehatan |
| Subjects: | |
| Online Access: | https://journal2.unusa.ac.id/index.php/JHS/article/view/5792 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850256783533146112 |
|---|---|
| author | Asbar Tanjung |
| author_facet | Asbar Tanjung |
| author_sort | Asbar Tanjung |
| collection | DOAJ |
| description | The intensive phase of anti-tuberculosis (TB) drug therapy consists of a combination of
antibiotics, including Isoniazid (INH), Rifampicin (RIF), Pyrazinamide (PZA), and
Ethambutol (EMB). The primary goal of this therapy is to inhibit the growth and spread
of Mycobacterium tuberculosis, preventing its migration from the lungs to other organs.
However, intensive-phase therapy may result in both major and minor side effects. This
study aims to analyze the hematological profiles of pulmonary TB patients undergoing
intensive-phase anti-tuberculosis treatment. The respondents were pulmonary TB
patients recruited from primary healthcare centers within the East Bekasi District,
Bekasi City. Those who met the sample criteria underwent hematological examinations,
including hemoglobin (Hb), hematocrit (HCT), red blood cell count, white blood cell
count, and platelet count. The tests were conducted using the electrical impedance
method with a hematology analyzer. The hematological examination revealed a trend of
low hemoglobin levels, with the average Hb recorded at 11.98 ± 8.65 g/dL.
Additionally, abnormal blood parameters were observed, with 33.3% of patients
experiencing erythropenia, 57% showing thrombocytopenia, 33% presenting
leukopenia, and 20% exhibiting leukocytosis. These findings confirm that intensive-
phase anti-tuberculosis therapy affects the hematological profiles of pulmonary TB
patients, highlighting the need for close monitoring during treatment.
|
| format | Article |
| id | doaj-art-47386bc035ec42e5b8162d1dc42f1b98 |
| institution | OA Journals |
| issn | 1978-6743 2477-3948 |
| language | English |
| publishDate | 2024-08-01 |
| publisher | Universitas Nahdlatul Ulama Surabaya |
| record_format | Article |
| series | Jurnal Ilmiah Kesehatan |
| spelling | doaj-art-47386bc035ec42e5b8162d1dc42f1b982025-08-20T01:56:34ZengUniversitas Nahdlatul Ulama SurabayaJurnal Ilmiah Kesehatan1978-67432477-39482024-08-01170310.33086/jhs.v17i03.5792Analysis of Hematological Examination Results in Pulmonary Tuberculosis (TB) Patients Undergoing Intensive Phase Anti-Tuberculosis Drug TherapyAsbar Tanjung0STIKes Prima IndonesiaThe intensive phase of anti-tuberculosis (TB) drug therapy consists of a combination of antibiotics, including Isoniazid (INH), Rifampicin (RIF), Pyrazinamide (PZA), and Ethambutol (EMB). The primary goal of this therapy is to inhibit the growth and spread of Mycobacterium tuberculosis, preventing its migration from the lungs to other organs. However, intensive-phase therapy may result in both major and minor side effects. This study aims to analyze the hematological profiles of pulmonary TB patients undergoing intensive-phase anti-tuberculosis treatment. The respondents were pulmonary TB patients recruited from primary healthcare centers within the East Bekasi District, Bekasi City. Those who met the sample criteria underwent hematological examinations, including hemoglobin (Hb), hematocrit (HCT), red blood cell count, white blood cell count, and platelet count. The tests were conducted using the electrical impedance method with a hematology analyzer. The hematological examination revealed a trend of low hemoglobin levels, with the average Hb recorded at 11.98 ± 8.65 g/dL. Additionally, abnormal blood parameters were observed, with 33.3% of patients experiencing erythropenia, 57% showing thrombocytopenia, 33% presenting leukopenia, and 20% exhibiting leukocytosis. These findings confirm that intensive- phase anti-tuberculosis therapy affects the hematological profiles of pulmonary TB patients, highlighting the need for close monitoring during treatment. https://journal2.unusa.ac.id/index.php/JHS/article/view/5792TuberculosisHematologyAnemiaOAT treatmentSide effects |
| spellingShingle | Asbar Tanjung Analysis of Hematological Examination Results in Pulmonary Tuberculosis (TB) Patients Undergoing Intensive Phase Anti-Tuberculosis Drug Therapy Jurnal Ilmiah Kesehatan Tuberculosis Hematology Anemia OAT treatment Side effects |
| title | Analysis of Hematological Examination Results in Pulmonary Tuberculosis (TB) Patients Undergoing Intensive Phase Anti-Tuberculosis Drug Therapy |
| title_full | Analysis of Hematological Examination Results in Pulmonary Tuberculosis (TB) Patients Undergoing Intensive Phase Anti-Tuberculosis Drug Therapy |
| title_fullStr | Analysis of Hematological Examination Results in Pulmonary Tuberculosis (TB) Patients Undergoing Intensive Phase Anti-Tuberculosis Drug Therapy |
| title_full_unstemmed | Analysis of Hematological Examination Results in Pulmonary Tuberculosis (TB) Patients Undergoing Intensive Phase Anti-Tuberculosis Drug Therapy |
| title_short | Analysis of Hematological Examination Results in Pulmonary Tuberculosis (TB) Patients Undergoing Intensive Phase Anti-Tuberculosis Drug Therapy |
| title_sort | analysis of hematological examination results in pulmonary tuberculosis tb patients undergoing intensive phase anti tuberculosis drug therapy |
| topic | Tuberculosis Hematology Anemia OAT treatment Side effects |
| url | https://journal2.unusa.ac.id/index.php/JHS/article/view/5792 |
| work_keys_str_mv | AT asbartanjung analysisofhematologicalexaminationresultsinpulmonarytuberculosistbpatientsundergoingintensivephaseantituberculosisdrugtherapy |